REM Sleep Behavior Disorder: Clinical Trials

3 trials for REM Sleep Behavior Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3
Phase 11Completed 1

Follow REM Sleep Behavior Disorder: new trials by email Literature Review of REM Sleep Behavior Disorder trials Research Report on REM Sleep Behavior Disorder

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls
(11C)PE2I, Ioflupane - Parkinson Disease, REM Sleep Behavior Disorder
Phase 1 / Phase 2CompletedWeill Medical College of Cornell University822018-08-142025-03-12
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
Nelotanserin, Placebo - Dementia With Lewy Bodies, REM Sleep Behavior Disorder
Phase 2CompletedAxovant Sciences Ltd.342016-03-012020-05-20
Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism
Clonazepam, Placebo - REM Sleep Behavior Disorder
Phase 2CompletedSeoul National University Hospital402015-03-012016-04-25

Narrower conditions

Parkinson Disease (2)  ·  Lewy Body Disease (1)

Broader conditions

Basal Ganglia Diseases (3)  ·  Brain Diseases (3)  ·  Central Nervous System Diseases (3)  ·  Mental Disorders (3)  ·  Movement Disorders (3)  ·  Nervous System Diseases (3)  ·  Neurodegenerative Diseases (3)  ·  Parasomnias (3)  ·  Parkinsonian Disorders (3)  ·  REM Sleep Parasomnias (3)  ·  Sleep Wake Disorders (3)  ·  Synucleinopathies (3)  ·  Dementia (1)  ·  Neurocognitive Disorders (1)

Interventions

Clonazepam (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  N-(3-iodoprop-2-enyl)-2-beta-carbomethoxy-3-(4-methylphenyl)nortropane (1)  ·  ioflupane (1)  ·  nelotanserin (1)

Sponsors

Axovant Sciences Ltd. (1)  ·  Seoul National University Hospital (1)  ·  Weill Medical College of Cornell University (1)

Countries

United States (2)  ·  South Korea (1)

Top investigators

Alexander Shtilbans, MD (1)  ·  Beom Seok Jeon, MD, Ph.D (1)  ·  Ilise Lombardo, MD (1)

Results publications

PMID 33714847

NIH funding

R01NS095562 (1)